Continuation of ACEi and/or ARBs for Chronic Kidney Disease

Overseen by Elaine Ku, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of California, San Francisco

No Placebo Group

Trial Summary

What is the purpose of this trial?

The American Heart Association guidelines for high blood pressure (BP) currently recommend using angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) as first-line therapy for patients with chronic kidney disease (CKD) stage 3 or above. However, the prevalence of ACEi and ARB use in patients with CKD stage 4 or 5 is low, and current BP guidelines acknowledge the lack of solid evidence to support the benefit of using these agents in advanced CKD.This study seeks to conduct a pilot trial to determine the safety and feasibility of ACEi and/or ARB continuation (intervention) versus withdrawal (control) in patients with advanced CKD.

Research Team

Elaine Ku, MD

Principal Investigator

University of California, San Francisco

Eligibility Criteria

Inclusion Criteria

adults ≥18 years of age who meet the eGFR eligibility criteria, which will be determined based on whether participants have at least two eGFR in the last three months that are < 25 mL/min/1.73m2 or prior diagnosis of CKD (per electronic chart review) and at least one eGFR < 25 mL/min/1.73m2 in the past six months

receiving at least one antihypertensive medication at the time of the screening visit

Exclusion Criteria

You don't want to agree to participate in the study.

are marginally housed, due to concerns regarding routine follow-up

are or are planning to become pregnant, due to inability to take multiple classes of anti-hypertensive agents

Treatment Details

Interventions

• Continuation of ACEi and/or ARBs (ACE inhibitor/ARB)

Participant Groups

Group I: ACEi/ARB continuation Experimental Treatment 1 Intervention

Intervention group will continue or start to take ACEi and/or ARBs

Group II: ACEi/ARB withdrawal Active Control 1 Intervention

The control group will discontinue ACEi and/or ARBs which may be substituted with other anti-hypertensive agents (if already taking ACEi/ARB) or continue to not take ACEi/ARBs

Who Is Running the Clinical Trial?

University of California, San Francisco

Lead Sponsor

Trials

2,636

Recruited

19,080,000+